Surrozen Inc (SRZN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Surrozen Inc (SRZN) has a cash flow conversion efficiency ratio of 0.034x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.42 Million) by net assets ($-218.66 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SRZN stock market capitalisation for the company's overall valuation and market capitalisation.
Surrozen Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Surrozen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Surrozen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Surrozen Inc ranked by their cash flow conversion efficiency. Explore earnings quality score of Surrozen Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TMC Life Sciences Bhd
KLSE:0101
|
0.010x |
|
Genomictree Inc.
KQ:228760
|
-0.028x |
|
Yuan Jen Enterprises Co Ltd
TW:1725
|
-0.002x |
|
Security National Financial
NASDAQ:SNFCA
|
0.009x |
|
Hillgrove Resources Ltd
AU:HGO
|
0.266x |
|
Autosports Group Ltd
AU:ASG
|
0.043x |
|
Landmark Bancorp Inc
NASDAQ:LARK
|
0.020x |
|
United Bankers Oyj
HE:UNITED
|
0.022x |
Annual Cash Flow Conversion Efficiency for Surrozen Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Surrozen Inc from 2019 to 2025. View Surrozen Inc (SRZN) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-187.76 Million | $-30.24 Million | 0.161x | -80.46% |
| 2024-12-31 | $-21.38 Million | $-17.63 Million | 0.825x | +177.49% |
| 2023-12-31 | $37.94 Million | $-40.36 Million | -1.064x | -83.18% |
| 2022-12-31 | $76.00 Million | $-44.15 Million | -0.581x | -30.54% |
| 2021-12-31 | $109.70 Million | $-48.81 Million | -0.445x | +27.68% |
| 2020-12-31 | $47.29 Million | $-29.10 Million | -0.615x | +14.13% |
| 2019-12-31 | $29.39 Million | $-21.06 Million | -0.717x | -- |
About Surrozen Inc
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, … Read more